NYSE · RCUS
Healthcare · Biotechnology
$29.06
Down-$0.60 (-2.02%)
Updated Sep 9, 2026, 5:57 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RCUS closed at $29.06 after 20 trading sessions, up 1.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $29.21 | $29.50 | $28.79 | $29.06 | 1.36M |
| Sep 4, 2026 | $29.64 | $30.10 | $29.40 | $29.66 | 736.98K |
| Sep 3, 2026 | $29.92 | $30.20 | $29.195 | $30.13 | 681.7K |
| Sep 2, 2026 | $30.17 | $31.47 | $29.32 | $29.85 | 1.23M |
| Sep 1, 2026 | $29.18 | $29.87 | $28.68 | $29.71 | 1.53M |
| Aug 31, 2026 | $28.89 | $29.345 | $28.2274 | $29.28 | 1.11M |
| Aug 28, 2026 | $30.13 | $30.435 | $29.06 | $29.21 | 1.09M |
| Aug 27, 2026 | $30.75 | $31.01 | $30.36 | $30.59 | 806.06K |
| Aug 26, 2026 | $31.34 | $31.455 | $30.30 | $30.76 | 685.58K |
| Aug 25, 2026 | $30.11 | $31.58 | $30.11 | $31.57 | 655.7K |
| Aug 24, 2026 | $30.27 | $30.91 | $29.38 | $30.12 | 1.3M |
| Aug 21, 2026 | $29.89 | $30.56 | $29.74 | $30.34 | 1.06M |
| Aug 20, 2026 | $29.88 | $30.39 | $28.94 | $29.52 | 1.55M |
| Aug 19, 2026 | $30.44 | $31.28 | $30.04 | $30.35 | 1.82M |
| Aug 18, 2026 | $29.23 | $29.8625 | $28.94 | $29.51 | 896.39K |
| Aug 17, 2026 | $29.32 | $30.045 | $28.9233 | $29.56 | 2.17M |
| Aug 14, 2026 | $28.55 | $29.68 | $27.97 | $29.48 | 1.15M |
| Aug 13, 2026 | $29.13 | $29.30 | $28.615 | $28.86 | 984.9K |
| Aug 12, 2026 | $28.87 | $29.25 | $28.67 | $28.96 | 943.85K |
| Aug 11, 2026 | $28.82 | $29.345 | $27.95 | $28.74 | 766.89K |
The latest Smart Investors Daily articles mentioning RCUS.
RCUS research
Company profile and research snapshot.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 4, 2026 | LifeSci Capital | Outperform | — |
No generated briefing is available yet.
ChartMill · Aug 27, 2026
ARCUS BIOSCIENCES (RCUS): Technical rating 10/10, setup 9/10. Trading near $31 resistance, a breakout offers a defined entry with clear stop levels.
Yahoo · Aug 26, 2026
HAYWARD, Calif., August 26, 2026--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:
Benzinga · Aug 6, 2026
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
Benzinga · Aug 6, 2026
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RCUS.
